drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous anti‑CD19 CAR T‑cell therapy with a 4‑1BB co‑stimulatory domain and CD3ζ signaling, engineered to recognize and kill CD19‑positive B cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Tisagenlecleucel
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells genetically engineered to express an anti‑CD19 chimeric antigen receptor with a 4‑1BB co‑stimulatory domain and CD3ζ signaling. Upon binding CD19 on B cells, the CAR activates T‑cell cytotoxicity, proliferation, and cytokine release to eliminate CD19‑positive malignant B cells and promote persistence.
drug_name
Tisagenlecleucel (tisa‑cel)
nct_id_drug_ref
NCT06458439